ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
TRT to Supraphysiological Levels for Body Building
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tareload" data-source="post: 216469"><p>[URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392149/[/URL]</p><p></p><p>[URL unfurl="true"]https://www.mdpi.com/2073-4409/10/8/2067/pdf[/URL]</p><p></p><p>=====</p><p>Finally, all the results reported in the present meta-analysis should be cautiously evaluated, considering the high degree of heterogeneity among included studies. This variability is due to the absence of shared evidence-based parameters that are able to measure the lean body compartment, and to the high variability among studies in terms of the inclusion criteria, the mode of measurement of body composition, the androgenic compounds selected, dosages, and scheme and route of administration. In addition, while only a few trials were designed to assess the lean mass compartment change in HIV settings, thus limiting data availability, <span style="font-size: 15px"><em><strong>the androgen therapeutic schemes were offered for a maximum of six months, making long-term considerations impossible [<em>EDIT my comment: most were 12 weeks</em>]. </strong></em></span>All these parameters should be considered, together with the low quality of the included studies, as depicted in the risk of bias evaluation, suggesting the high levels of difficulty involved in designing a clinical trial in HIV-infected patients.</p><p></p><p></p><p>In conclusion, our systematic review highlights an increased prevalence of hypogonadism in the young to middle-aged HIV-population compared to uninfected men. However, this comorbidity could remain neglected when only TT serum levels are measured. Interestingly, reduced Te serum levels reflect poor disease control, which was related to CD4+ cell count. In HIV-infected men, chronic androgen supplementations seem to exert a significant impact on body composition, particularly affecting the lean mass compartment. Indeed, the androgenic treatment for anabolic purposes in HIV male patients leads to a mild improvement of some body composition parameters, although this is not predictable. <span style="font-size: 18px"><strong>Moreover, since the vast majority of trials set up short-term treatment schemes, no data are currently available regarding the long-term effects of androgen administration in a HIV setting. Considering the general frailty of HIV patients and the significant burden of adverse effects that characterizes anabolic androgenic therapy, a personalized and tailored therapeutic approach is mandatory in such patients.</strong></span></p><h2></h2><p>=====</p><p>Wow, since you played the confirmation bias card, I'll make sure to go through each one of the studies in the supplementary material one by one.</p></blockquote><p></p>
[QUOTE="tareload, post: 216469"] [URL unfurl="true"]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392149/[/URL] [URL unfurl="true"]https://www.mdpi.com/2073-4409/10/8/2067/pdf[/URL] ===== Finally, all the results reported in the present meta-analysis should be cautiously evaluated, considering the high degree of heterogeneity among included studies. This variability is due to the absence of shared evidence-based parameters that are able to measure the lean body compartment, and to the high variability among studies in terms of the inclusion criteria, the mode of measurement of body composition, the androgenic compounds selected, dosages, and scheme and route of administration. In addition, while only a few trials were designed to assess the lean mass compartment change in HIV settings, thus limiting data availability, [SIZE=15px][I][B]the androgen therapeutic schemes were offered for a maximum of six months, making long-term considerations impossible [[I]EDIT my comment: most were 12 weeks[/I]]. [/B][/I][/SIZE]All these parameters should be considered, together with the low quality of the included studies, as depicted in the risk of bias evaluation, suggesting the high levels of difficulty involved in designing a clinical trial in HIV-infected patients. In conclusion, our systematic review highlights an increased prevalence of hypogonadism in the young to middle-aged HIV-population compared to uninfected men. However, this comorbidity could remain neglected when only TT serum levels are measured. Interestingly, reduced Te serum levels reflect poor disease control, which was related to CD4+ cell count. In HIV-infected men, chronic androgen supplementations seem to exert a significant impact on body composition, particularly affecting the lean mass compartment. Indeed, the androgenic treatment for anabolic purposes in HIV male patients leads to a mild improvement of some body composition parameters, although this is not predictable. [SIZE=18px][B]Moreover, since the vast majority of trials set up short-term treatment schemes, no data are currently available regarding the long-term effects of androgen administration in a HIV setting. Considering the general frailty of HIV patients and the significant burden of adverse effects that characterizes anabolic androgenic therapy, a personalized and tailored therapeutic approach is mandatory in such patients.[/B][/SIZE] [HEADING=1][/HEADING] ===== Wow, since you played the confirmation bias card, I'll make sure to go through each one of the studies in the supplementary material one by one. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
TRT to Supraphysiological Levels for Body Building
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top